Type 1 Diabetes Trial, Recruiting NCT05546138 Sponsor: Aalborg University Hospital Condition: Type 1 Diabetes
Back to Type 1 Diabetes

Type 1 Diabetes Trial, Recruiting

NCT05546138
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People between 18 and 80 years old (men and women).
  • People who have been diagnosed with diabetes, of any type.
  • People who have not already been diagnosed with diabetic nerve damage in their feet or legs at the time of joining.

Who may not be able to join:

  • People who have had problems with alcohol or drug misuse in the past year.
  • People who have received or are receiving chemotherapy, or who are taking any experimental medicines.
  • People with severe vitamin deficiencies.
  • People who are unable to understand or follow the procedures involved in the study.
  • People who are likely to stop receiving care at Aalborg University Hospital during the study period.
  • People with a known blood disorder that makes it very difficult for small cuts or wounds to stop bleeding.
  • People with severely reduced blood flow to their limbs.
  • People who currently have an open diabetic foot wound or ulcer.
  • People who have previously had an amputation.
  • People with severe skin conditions, or conditions known to cause nerve damage.
  • People who are pregnant at the time of joining the trial.

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 28 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Peter Vestergaard, PhD, Steno Diabetes Center North Denmark

Phone: +45 97663651

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Sponsor
Aalborg University Hospital
Registry
ClinicalTrials.gov
Start date
1 October 2023
Est. completion
31 December 2029

Where this trial is recruiting

🇩🇰 Denmark

Primary endpoints

Prediction of early onset neuropathy; Comparison of Perception Threshold Tracking (PTT) and skin biopsies; Progression and regression of neuropathy

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov